Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma
Naing A, LoRusso P, Mills G, Berry D, Doyle L, Rohren E, Burger A, Chen H, Busaidy N, Kurzrock R. Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma. Journal Of Clinical Oncology 2009, 27: e14535-e14535. DOI: 10.1200/jco.2009.27.15_suppl.e14535.Peer-Reviewed Original ResearchIMC-A12MTOR inhibitorsDose cohortsSolid tumorsBiologic effectsType I insulin-like growth factor receptorCommon grade 1Dose-escalation cohortsImmunosuppressive agent sirolimusLambda monoclonal antibodySolid tumor histologiesGrade 2 toxicityAdvanced solid tumorsHistory of diabetesI insulin-like growth factor receptorInsulin-like growth factor receptorCombination of temsirolimusGrowth factor receptorStable diseaseEscalation cohortsWeekly doseTumor histologyGrade 3IGFR inhibitorsTherapeutic effect